Crossref
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect comparison method
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14130 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Hauptthemen laut MEDLINE: Hemophilia A, Glycoproteins.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Hemophilia AGlycoproteinsHumansHalf-LifeFactor VIIIRecombinant ProteinsTreatment Outcome
Substanzen
simoctocog alfa (Nuwiq)Factor VIIIRecombinant ProteinsGlycoproteins
Zitieren
APA
(2024). Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect comparison method. European Journal of Haematology. https://doi.org/10.1111/ejh.14130
Vancouver
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect comparison method. European Journal of Haematology. 2024. doi:10.1111/ejh.14130
BibTeX
@article{euvimed2024,
title = {Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect comparison method},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14130}
}
EUVIMED